Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.

@article{Leitner2011PathogenicCB,
  title={Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.},
  author={Eike-Christin von Leitner and Anna Klinke and Dorothee Atzler and Jessica L. Slocum and Natalie Lund and Jan T Kielstein and Renke Maas and Robin Schmidt-Haupt and Michaela Pekarov{\'a} and Olaf J. C. Hellwinkel and Dimitrios Tsikas and L G D'alecy and Denise Lau and Stephan Willems and Luk{\'a}{\vs} Kubala and Heimo Ehmke and Thomas Meinertz and Stefan S Blankenberg and Edzard Schwedhelm and Crystal Ann Gadegbeku and Rainer H. B{\"o}ger and Stephan Baldus and Karsten Sydow},
  journal={Circulation},
  year={2011},
  volume={124 24},
  pages={2735-45}
}
BACKGROUND The nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and the leukocyte-derived hemoprotein myeloperoxidase (MPO) are associated with cardiovascular diseases. Activation of monocytes and polymorphonuclear neutrophils (PMNs) with concomitant release of MPO is regulated in a nitric oxide-dependent fashion. The aim of the study was to investigate a potential 2-way interaction between ADMA and MPO. METHODS AND RESULTS Ex vivo, ADMA uptake by isolated human PMNs, the… CONTINUE READING